# NCT02003222 (NCT02003222)

> Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02003222
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: National Cancer Institute (NCI)
- Conditions: Acute Lymphoblastic Leukemia; B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
- Interventions: Allogeneic Hematopoietic Stem Cell Transplantation; Biospecimen Collection; Blinatumomab; Bone Marrow Aspiration; Bone Marrow Biopsy; Cyclophosphamide; Cytarabine; Daunorubicin; Daunorubicin Hydrochloride; Dexamethasone; Etoposide; Leucovorin Calcium; Lumbar Puncture; Mercaptopurine; Methotrexate; Pegaspargase; Prednisone; Rituximab; Vincristine; Vincristine Sulfate; X-Ray Imaging
- Enrollment: 488
- Primary outcome: Overall Survival (OS) Among Patients Who Were MRD Negative After Induction and Intensification Chemotherapy

## Commentary we found

- X threads: 23
- YouTube: 18
- Podcasts: 15

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct02003222

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02003222", "email": "<work email>"}; the inbox owner confirms by the emailed link.